Literature DB >> 22868220

Clinical implications and added costs of incidental findings in an early detection study of lung cancer by using low-dose spiral computed tomography.

Adriano M Priola1, Sandro M Priola, Matteo Giaj-Levra, Edoardo Basso, Andrea Veltri, Cesare Fava, Luciano Cardinale.   

Abstract

INTRODUCTION: To prospectively evaluate the frequency and spectrum of incidental findings (IF) in a 5-year lung cancer screening program with low-dose spiral computed tomography (CT) and to estimate the additional costs of their imaging workup incurred from subsequent radiologic follow-up evaluation.
MATERIALS AND METHODS: A total of 519 asymptomatic volunteers were enrolled. All IFs were reported and were considered clinically relevant if they required further evaluations or with clinical implications if they required more than one additional diagnostic test for characterization or medical and/or surgical intervention.
RESULTS: IFs were commonly found (59.2%, 307/519 participants at baseline and 5.3% per year at 5-year follow-up [123 participants of 2341 LDsCT exams performed during follow-up], with an overall rate of 26.3%). IFs were categorized as previously unknown clinically relevant in 52 (10.0%) individuals at baseline. Of these, 36 (6.9%) individuals had IFs with clinical implications (10 clinically relevant, of which 6 had clinical implications, detected during the subsequent 5-year follow-up). The most common recommendations were for additional imaging of the thyroid and kidneys. Additional imaging was mainly performed by ultrasound (43/68 [63.2%]). Subsequent surgical intervention resulted from these findings in 7 (1.5%) subjects. Six malignancies were diagnosed (rate, 0.2% per year). Costs of subsequent radiologic follow-up studies were calculated as €4644.56 [U.S. $6575.04] at baseline and €1052.30 [U.S. $1489.69] at 5-year follow-up (average added costs per participant €8.95 [U.S. $12.67] and €2.25 [U.S. $3.19], respectively).
CONCLUSIONS: Low-dose spiral CT commonly detects IFs. Some of these require further investigations to assess their clinical relevance. Although such IFs add little clinical benefit to the screening intervention, moderate incremental costs are incurred based on additional radiologic procedures generated during short-term follow-up, given the potential for positive effects on patient care.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22868220     DOI: 10.1016/j.cllc.2012.05.005

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  24 in total

1.  Performance of ultralow-dose CT with iterative reconstruction in lung cancer screening: limiting radiation exposure to the equivalent of conventional chest X-ray imaging.

Authors:  Adrian Huber; Julia Landau; Lukas Ebner; Yanik Bütikofer; Lars Leidolt; Barbara Brela; Michelle May; Johannes Heverhagen; Andreas Christe
Journal:  Eur Radiol       Date:  2016-01-26       Impact factor: 5.315

Review 2.  Computed tomography screening for lung cancer in the National Lung Screening Trial: a cost-effectiveness analysis.

Authors:  William C Black
Journal:  J Thorac Imaging       Date:  2015-03       Impact factor: 3.000

3.  Association of Coronary Artery Calcification and Mortality in the National Lung Screening Trial: A Comparison of Three Scoring Methods.

Authors:  Caroline Chiles; Fenghai Duan; Gregory W Gladish; James G Ravenel; Scott G Baginski; Bradley S Snyder; Sarah DeMello; Stephanie S Desjardins; Reginald F Munden
Journal:  Radiology       Date:  2015-03-09       Impact factor: 11.105

4.  Normal thymus in adults: appearance on CT and associations with age, sex, BMI and smoking.

Authors:  Tetsuro Araki; Mizuki Nishino; Wei Gao; Josée Dupuis; Gary M Hunninghake; Takamichi Murakami; George R Washko; George T O'Connor; Hiroto Hatabu
Journal:  Eur Radiol       Date:  2015-04-30       Impact factor: 5.315

5.  Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare.

Authors:  Joshua A Roth; Sean D Sullivan; Bernardo H L Goulart; Arliene Ravelo; Joanna C Sanderson; Scott D Ramsey
Journal:  J Oncol Pract       Date:  2015-05-05       Impact factor: 3.840

6.  Doubling time of thymic epithelial tumours on CT: correlation with histological subtype.

Authors:  Jooae Choe; Sang Min Lee; Soyeoun Lim; Se Hoon Choi; Namkug Kim; Kyung-Hyun Do; Joon Beom Seo
Journal:  Eur Radiol       Date:  2017-03-22       Impact factor: 5.315

7.  Diffusion-weighted magnetic resonance imaging of thymoma: ability of the Apparent Diffusion Coefficient in predicting the World Health Organization (WHO) classification and the Masaoka-Koga staging system and its prognostic significance on disease-free survival.

Authors:  Adriano Massimiliano Priola; Sandro Massimo Priola; Maria Teresa Giraudo; Dario Gned; Alessandro Fornari; Bruno Ferrero; Lorena Ducco; Andrea Veltri
Journal:  Eur Radiol       Date:  2015-10-01       Impact factor: 5.315

Review 8.  Extrapulmonary neoplasms in lung cancer screening.

Authors:  Myrna C B Godoy; Charles S White; Jeremy J Erasmus; Carol C Wu; Mylene T Truong; Reginald F Munden; Caroline Chiles
Journal:  Transl Lung Cancer Res       Date:  2018-06

9.  Five-year malignancy incidence in patients with chronic pruritus: a population-based cohort study aimed at limiting unnecessary screening practices.

Authors:  Nicole Fett; Kevin Haynes; Kathleen Joy Propert; David J Margolis
Journal:  J Am Acad Dermatol       Date:  2014-01-28       Impact factor: 11.527

10.  Normative reference values of thoracic aortic diameter in American College of Radiology Imaging Network (ACRIN 6654) arm of National Lung Screening Trial.

Authors:  Barbara L McComb; Reginald F Munden; Fenghai Duan; Amanda A Jain; Catherine Tuite; Caroline Chiles
Journal:  Clin Imaging       Date:  2016-04-26       Impact factor: 1.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.